SecBot SecBot
PRESS-RELEASE ·Filed Jun 12, 2026

KYMR

Kymera Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine clinical update with no material new data, the stock is unlikely to move on this announcement alone. Monitor Phase 2b data readouts in mid-2027 (AD) and late 2027 (asthma) as the next major catalysts. No trading action warranted.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$86.21
T+0 close · Jun 12, 2026 · via day close
Latest settled
+35.11%
T+60 · $116.47
Vs SPY
+31.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 12 $86.21entry
  2. T+1 · 5mo ago −0.71%α −2.48% · $85.59
  3. T+5 · 5mo ago +4.90%α +4.23% · $90.43
  4. T+20 · 4mo ago +38.45%α +36.67% · $119.35
  5. T+60 · 2mo ago +35.11%α +31.84% · $116.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, showing safety and PK/PD results consistent with prior studies. The data supports global Phase 2b trials (BROADEN2 in atopic dermatitis, BREADTH in asthma) that are ongoing with readouts expected by mid-2027 and late 2027, respectively. This is an incremental data update with no new efficacy or regulatory catalyst, a routine clinical-stage update for a $6.8B biotech.

Key Facts

  • Phase 1 study in 24 healthy Japanese adults showed median STAT6 degradation ≥98% at both dose levels at Day 7, consistent with prior non-Japanese studies.
  • KT-621 was well tolerated with a favorable safety profile across both doses.
  • Parallel Phase 2b trials BROADEN2 (atopic dermatitis) and BREADTH (asthma) are ongoing; data expected by mid-2027 and late 2027, respectively.
  • No new efficacy data, regulatory milestone, or financial guidance was disclosed in this press release.

Financial Impact

No financial figures disclosed; this is a clinical data update with no immediate revenue or cost impact.

Risk Factors

  • Phase 2b data may fail to replicate Phase 1 efficacy or safety signals.
  • Competition from other oral STAT6/Type 2 inflammation programs (e.g., from Roche, Sanofi) could limit commercial potential.
  • Cash burn from ongoing trials without near-term revenue may pressure the stock if financing is needed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310977

Track record

37 reports on KYMR

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
  2. Oct 29, 202618d ago 8-K Neutral 5/10 No price data
  3. Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
  4. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
  5. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
  9. Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 12, 2026